Obesity is a worldwide problem of epidemic proportions associated with diabetes, cardiovascular disease, respiratory failure, muscle weakness, and cancer.

The World Health Organization estimates that there are more than a billion overweight adults, of whom at least 300 million are obese (1).

Drugs that help reduce body weight provide benefits both in obesity and obesity-associated comorbidities. However, many weight-loss medications have been withdrawn from the market because of serious adverse effects (2). Because of these, only five medications have been approved for the management of obesity, and none of them acts directly against fat metabolism while avoiding fat absorption and/or acting on the CNS to decrease appetite.

Landsteiner Genmed NPO-2237 is a compound with a new mechanism of action that acts against fat metabolism, preventing its accumulation in the body, as well as decreasing glycemia in a diet-induced obesity model. It has demonstrated in vivo efficacy similar to that of liraglutide (see below), with an excellent safety profile.

(1) D. P. Guh, W. Zhang, N. Bansback, Z. Amarsi, C. L. Birmingham, and A. H. Anis, “The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis,” BMC Public Health 2009; 9, article 88
(2) W. Rankin & G. Wittert. Anti-obesity drugs. Current Opinion in Lipidology, 2015; 26, 536-543

For further information about our studies

Ask us